2025
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses
Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.Peer-Reviewed Original ResearchProgression free survivalWhole-exome sequencingImmune checkpoint inhibitorsOverall survivalEndometrial cancerMicrosatellite instability-highCheckpoint inhibitorsFree survivalFollow-upResponse to immune checkpoint inhibitorsPatients treated with pembrolizumabProspective phase II studyExome sequencingResponse rateRecurrent platinum-resistantPhase II studyPhase 2 trialOverall survival dataEndometrial cancer patientsMLH-1MSI-H patientsFoundationOne platformImproved OSUpdate survivalPrognostic significanceRapid response to behavioral/pharmacological obesity treatments for binge‐eating disorder predicts better clinical outcomes
Lydecker J, Gueorguieva R, Grilo C. Rapid response to behavioral/pharmacological obesity treatments for binge‐eating disorder predicts better clinical outcomes. Obesity 2025, 33: 1067-1075. PMID: 40265670, DOI: 10.1002/oby.24292.Peer-Reviewed Original ResearchConceptsBinge-eating disorderBinge-eating remissionEating-disorder psychopathologyAssociated with greater reductionsObesity treatmentCo-occurring obesityBinge-eating frequencyClinical trial testingBehavioral therapyNon-rapid responseGreater reductionsPercent weight lossNaltrexone/bupropionRandomized clinical trial testingDisordersPrognostic significanceParticipantsPosttreatmentClinical characteristicsPrognostic indicatorClinical outcomesMetabolic outcomesResponse effectMetabolic variablesObesity interventionsIntracerebral haemorrhage laterality and associations with mood and pain: a MISTIE III substudy
Cooper D, Abramson E, Ziai W, Flaherty M, Shah V, Avadhani R, Ostapkovich N, Carhuapoma L, Awad I, Zuccarello M, Hanley D, Sansing L. Intracerebral haemorrhage laterality and associations with mood and pain: a MISTIE III substudy. Stroke And Vascular Neurology 2025, svn-2024-003755. PMID: 40250866, DOI: 10.1136/svn-2024-003755.Peer-Reviewed Original ResearchNon-motor outcomesSupratentorial intracerebral haemorrhageModified Rankin ScaleMinimally invasive surgeryIntracerebral haemorrhageReport problemsPost-ICHStandard medical careAssociated with increased reportingThree-level versionImpact patient recoveryInvasive surgeryTrials of participantsAssociated with moodModified Rankin Scale scorePlacebo-controlled trialEvaluating minimally invasive surgeryAffected hemisphereIntracerebral hemorrhage evacuationMedical careAcute intracerebral haemorrhageMood-related symptomsHaemorrhagic strokePrognostic significanceWell-beingTP53‐Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis
Chen D, Cantu M, Siddon A, Weinberg O. TP53‐Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis. European Journal Of Haematology 2025, 115: 57-63. PMID: 40152319, PMCID: PMC12134709, DOI: 10.1111/ejh.14421.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaTP53-mutated acute myeloid leukemiaBlast phase myeloproliferative neoplasmsTP53 mutationsClinical outcomesMPN-BPMyeloproliferative neoplasmsMyeloid leukemiaAssociated with prognostic significanceMissense mutationsLow-risk groupSplice site variantOverall survivalAssociated with relatively better prognosisMyeloid neoplasmsPrognostic significanceBetter prognosisTP53 mutantsTherapeutic responseRisk stratificationRetrospective analysisExon 5TP53Exon 6Poorer PrognosisNCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
Greenberg P, Stone R, Abaza Y, Al-Kali A, Anand S, Ball B, Bennett J, Borate U, Brunner A, Chai-Ho W, Curtin P, DeZern A, Gaensler K, Gahvari Z, Garcia-Manero G, Griffiths E, Haque T, Jacoby M, Jonas B, Keel S, Khanal R, Kishtagari A, Madanat Y, Maness L, McCurdy S, McMahon C, Odenike O, Osman A, Reddy V, Sallman D, Sayar H, Shallis R, Singh A, Tanaka T, Thota S, Kovach E, Nguyen J, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. Journal Of The National Comprehensive Cancer Network 2025, 23: 66-75. PMID: 40073835, DOI: 10.6004/jnccn.2025.0013.Peer-Reviewed Original ResearchConceptsNCCN Guidelines InsightsHigher-risk MDSComprehensive care of patientsPrognostic significanceNCCN guidelinesClinical evidenceCare of patientsTreatment recommendationsMultidisciplinary panelNovel therapeuticsTherapeutic agentsNCCNLowered riskComprehensive careTreatmentBiological factorsPatientsA pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
Mukhtar R, Gottipati S, Yau C, López-Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, van der Noordaa M, de Croze D, Hamy A, Laé M, Reyal F, Sonke G, Steenbruggen T, van Seijen M, Wesseling J, Martín M, del Monte-Millán M, Boughey J, Goetz M, Hoskin T, Valero V, Edge S, Abraham J, Bartlett J, Caldas C, Dunn J, Provenzano E, Sammut S, Thomas J, Graham A, Hall P, Mackintosh L, Fan F, Godwin A, Schwensen K, Sharma P, DeMichele A, Cole K, Pusztai L, Kim M, J van ’t Veer L, Cameron D, Esserman L, Fraser Symmans W. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer. Npj Breast Cancer 2025, 11: 14. PMID: 39948079, PMCID: PMC11825822, DOI: 10.1038/s41523-025-00720-3.Peer-Reviewed Original ResearchResidual cancer burdenInvasive lobular carcinomaEvent-free survivalNeoadjuvant chemotherapyBreast cancerAssociated with worse event-free survivalResidual cancer burden indexInvasive lobular breast cancerCancer burdenLobular breast cancerNodal statusLobular carcinomaNAC responseT categoryPrognostic significanceStratify prognosisPatient-level dataReceptor subtypesPooled analysisMultivariate analysisPooled cohortRecursive partitioningCox modelCancer cellularityCancerEvaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial.
Sokolova A, Tangen C, Hussain M, Sweeney C, Dorff T, Thompson I, Lerner S. Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial. Journal Of Clinical Oncology 2025, 43: 268-268. DOI: 10.1200/jco.2025.43.5_suppl.268.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerPSA responseAndrogen deprivation therapyProstate-specific antigenContinuous androgen deprivation therapyContinuous ADTOverall survivalDisease extentCox regressionHormone-sensitive prostate cancerAssociated with worse OSDe-intensification strategiesBaseline clinical featuresSubsets of patientsTreatment effectsDeprivation therapyImproved OSExtensive diseaseMinimal diseasePrognostic significanceProstate cancerOptimal therapyCox analysisLymph nodesPrognostic markerRetrospective Visual and Quantitative Assessment of Burst Suppression With and Without Identical Bursts in Patients After Cardiac Arrest
Fong M, Pu K, Beekman R, Kim N, Nguyen C, Gilmore E, Hirsch L, Zaveri H. Retrospective Visual and Quantitative Assessment of Burst Suppression With and Without Identical Bursts in Patients After Cardiac Arrest. Neurocritical Care 2025, 1-11. PMID: 39900751, DOI: 10.1007/s12028-024-02208-7.Peer-Reviewed Original ResearchIdentical burstsBurst suppressionCardiac arrest survivorsInterburst intervalClinical featuresNeurological outcomeCardiac arrestArrest survivorsAssociated with poor neurological outcomeContinuous electroencephalogramCerebral Performance Category scoreAssociated with poor outcomesCardiac arrest patientsPoor neurological outcomePost-cardiac arrestPredictors of mortalityUS academic medical centersEEG backgroundPrognostic significanceArrest patientsClinical outcomesPoor outcomeRetrospective analysisAcademic medical centerUS cohortPrevalence and prognostic impact of ST-segment elevation in lead aVR among patients with cardiac arrest
Banna S, Schenck C, Kim N, Ali T, Gilmore E, Greer D, Beekman R, Miller P. Prevalence and prognostic impact of ST-segment elevation in lead aVR among patients with cardiac arrest. European Heart Journal Acute Cardiovascular Care 2025, 14: 232-236. PMID: 39873390, DOI: 10.1093/ehjacc/zuaf018.Peer-Reviewed Original ResearchOut-of-hospital cardiac arrestAssociated with higher in-hospital mortalityHigher In-Hospital MortalityST-segment elevationIn-Hospital MortalityReturn of spontaneous circulationCardiac arrestShockable rhythmLead aVRPoor neurological outcomeAcute coronary syndromeMultivariate logistic regressionPrognostic impactPost-ROSCPrognostic significanceSpontaneous circulationCA patientsNeurological outcomeCoronary syndromeIdentified patientsMultivariable adjustmentMain diseasePatientsCA survivorsArrest characteristicsDiverse stromal phenotypes at spatial resolution in colorectal cancer peritoneal metastasis.
Zhao J, Ong J, Liu Y, Srivastava S, Teo M, Lee J, Walsh R, Loo L, Tan Q, Ng G, Tan J, Ma H, Ong X, Tay S, Sheng T, Lum J, Yong W, Pietrantonio F, Tan P, Sundar R. Diverse stromal phenotypes at spatial resolution in colorectal cancer peritoneal metastasis. Journal Of Clinical Oncology 2025, 43: 218-218. DOI: 10.1200/jco.2025.43.4_suppl.218.Peer-Reviewed Original ResearchCancer-associated fibroblastsT cell exhaustionPeritoneal metastasisT cellsStromal phenotypeColorectal cancerTissue microarrayStromal compartmentPoor prognosisSpatial distribution of T cellsColorectal cancer peritoneal metastasesIncreased CAFsClusters of T cellsCRC PMDistribution of T cellsTumor stroma compartmentAssociated with poor prognosisMemory B cellsDigital spatial profilingTranscoelomic disseminationTumor compartmentsStromal clustersPrognostic significanceTNF-alphaB cells
2024
Mouse Models Enable the Functional Investigation of Tertiary Lymphoid Structures in Cancer
Jeevanandam A, Yin Z, Connolly K, Joshi N. Mouse Models Enable the Functional Investigation of Tertiary Lymphoid Structures in Cancer. Methods In Molecular Biology 2024, 2864: 57-76. PMID: 39527217, DOI: 10.1007/978-1-0716-4184-2_4.Peer-Reviewed Original ResearchConceptsTertiary lymphoid structuresTertiary lymphoid structure formationSecondary lymphoid organsLymphoid structuresMurine modelFeatures of tertiary lymphoid structuresFunction of tertiary lymphoid structuresMouse modelPersistent inflammatory stimulationAssociated with positive clinical outcomesTissue-specific regulatory mechanismsPositive clinical outcomesPrognostic significanceClinical outcomesGut environmentNonlymphoid tissuesLymphoid aggregatesLymphoid organsMouse lungCancer patientsGenetic sequencesInflammatory stimulationRegulatory mechanismsTherapeutic modulationClinical effortsDNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance
Conway K, Edmiston S, Vondras A, Reiner A, Corcoran D, Shen R, Parrish E, Hao H, Lin L, Kenney J, Ilelaboye G, Kostrzewa C, Kuan P, Busam K, Lezcano C, Lee T, Hernando E, Googe P, Ollila D, Moschos S, Gorlov I, Amos C, Ernstoff M, Cust A, Wilmott J, Scolyer R, Mann G, Vergara I, Ko J, Rees J, Yan S, Nagore E, Bosenberg M, Rothberg B, Osman I, Lee J, Saenger Y, Bogner P, Thompson C, Gerstenblith M, Holmen S, Funchain P, Brunsgaard E, Depcik-Smith N, Luo L, Boyce T, Orlow I, Begg C, Berwick M, Thomas N, Berwick M, Luo L, Boyce T, Reynolds A, Wiggins C, Thomas N, Conway K, Edmiston S, Ollila D, Hao H, Parrish E, Googe P, Moschos S, Corcoran D, Vondras A, Tsai Y, Lin L, Shen R, Begg C, Arora A, Seshan V, Reiner A, Kostrzewa C, Busam K, Orlow I, Lezcano C, Kenney J, Sadeghi K, O'Connell K, Ilelaboye G, Parmar H, Leong S, Corrales S, Scolyer R, Cust A, Wilmott J, Mann G, Shang P, Burke H, Ferguson P, Jakrot V, Lee T, Hernando E, Osman I, Hanniford D, Argibay D, Moran U, Heguy A, Ramaswami S, Amos C, Gorlov I, Zhu D, Ernstoff M, Bogner P, Lee J, Rees J, Yan S, Gerstenblith M, Thompson C, Ko J, Funchain P, Ngo P, Bosenberg M, Gould Rothberg B, Panse G, Saenger Y, Fullerton B, Holmen S, Colman H, Brunsgaard E, Wada D, Nagore E, Manrique-Silva E, Requena C, Traves V, Millan-Esteban D, Rainka M. DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. JCO Precision Oncology 2024, 8: e2400375. PMID: 39509669, PMCID: PMC11737429, DOI: 10.1200/po-24-00375.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerCpG island methylator phenotypePrimary melanomaBreslow thicknessMethylation classClinicopathological characteristicsN stageRisk of melanoma-related deathLow methylationStage IIRetrospective case-control studyCutaneous primary melanomaHigher AJCC stagePrimary cutaneous melanomaHigher N stageMelanoma-related deathDNA methylation classDied of melanomaMitotic indexCase-control studyIII patientsClinicopathological factorsCpG island hypermethylationPrognostic significanceAJCC stageEvaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration
Mosquera Orgueira A, Perez Encinas M, Pérez Míguez C, Crucitti D, Piñeiro Fiel M, Díaz Varela N, Mora E, Díaz-Beyá M, Montoro M, Pomares H, Ramos Ortega F, Tormo M, Jerez A, Nomdedeu J, de Miguel Sanchez C, Arenillas L, Carcel Corella P, Cedena Romero M, Xicoy B, Rivero M, Del Orbe Barreto R, Bewersdorf J, Stahl M, Stempel J, Kewan T, Zeidan A, Diez-Campelo M, Valcarcel D. Evaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration. Blood 2024, 144: 6683-6683. DOI: 10.1182/blood-2024-198114.Peer-Reviewed Original ResearchLeukemia-free survivalPredictors of OSMyelodysplastic syndromeOverall survivalIPSS-MC-indexFLT3-ITDPredictors of leukemia-free survivalRevised International Prognostic Scoring SystemPrognostication of myelodysplastic syndromesInternational Prognostic Scoring SystemPrognostic scoring systemCox regression analysisMolecular dataClinical trial designIPSS-RGenetic variabilityMLL-PTDRandom survival forestPrognostic landscapePrognostic significanceLaboratory parametersAffected prognosisClinical predictorsClinical indicesTakotsubo cardiomyopathy and cardiogenic shock due to hypokalaemic rhabdomyolysis
Hwang E, Namburar S, Siegel M, Sanchez A. Takotsubo cardiomyopathy and cardiogenic shock due to hypokalaemic rhabdomyolysis. BMJ Case Reports 2024, 17: e261456. PMID: 39419603, DOI: 10.1136/bcr-2024-261456.Peer-Reviewed Original ResearchConceptsTakotsubo cardiomyopathyCardiogenic shockAssociated with Takotsubo cardiomyopathyConsistent with cardiogenic shockConsistent with takotsubo cardiomyopathyTriggers of takotsubo cardiomyopathyCentral venous oxygen saturationInfluence cardiac morbidityChronic idiopathic constipationLow central venous oxygen saturationST-segment elevationVenous oxygen saturationWorsening cardiomyopathyGlobal hypokinesisPrognostic significanceCardiac morbidityIdiopathic constipationSpiked helmet signSegment elevationECG patternOxygen saturationCardiomyopathyRhabdomyolysisEchocardiographyEating DisordersCyclic Alternating EEG Patterns: From Sleep to Encephalopathy
Misirocchi F, Mutti C, Hirsch L, Parrino L, Florindo I. Cyclic Alternating EEG Patterns: From Sleep to Encephalopathy. Journal Of Clinical Neurophysiology 2024, 41: 485-494. PMID: 39186585, DOI: 10.1097/wnp.0000000000001082.Peer-Reviewed Original ResearchConceptsCyclic alternating patternStandardized Critical Care EEG TerminologyCritical care EEG terminologyNon-rapid eye movement sleepAmerican Clinical Neurophysiology SocietyEye movement sleepCritically ill patientsEEG terminologyPrognostic significancePrognostic valueMovement sleepClinical significanceImpact of confounding factorsSleep instabilityCritical care settingIll patientsClinical importanceEEG activityEEG phenomenaSedative agentsElectrophysiological biomarkersAlternating patternEncephalopathySleepCare settingsCancer cell – Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma
Giangreco G, Rullan A, Naito Y, Biswas D, Liu Y, Hooper S, Nenclares P, Bhide S, Chon U Cheang M, Chakravarty P, Hirata E, Swanton C, Melcher A, Harrington K, Sahai E. Cancer cell – Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma. IScience 2024, 27: 110635. PMID: 39262776, PMCID: PMC11387794, DOI: 10.1016/j.isci.2024.110635.Peer-Reviewed Original ResearchTumor microenvironmentSquamous cell carcinoma cohortCancer cellsMacrophage chemo-attractantsSquamous cell carcinomaTumor-stroma crosstalkRecruitment of macrophagesExpression of CSF2Prognostic significanceCarcinoma cohortCell carcinomaPatient prognosisHB-EGFStromal fibroblastsCancer outcomesCancer progressionCancerMAPK signalingIndicator of signalingChemo-attractantsCellsFibroblastsCarcinomaExpressionEGFRAssociation Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.Peer-Reviewed Original ResearchDecipher genomic classifierRisk of metastasisBiochemical recurrenceRadical prostatectomyGenomic classifierDecipher testProstate cancerProstate Risk Assessment Postsurgical ScoreRisk of biochemical recurrencePatient's prostate cancerRisk of cancer recurrencePathological risk factorsProstate cancer outcomesCox proportional hazards regressionRetrospective cohort studyElectronic health record dataReal-world settingsProportional hazards regressionHealth record dataReal-world practice settingsProstate biopsyRP specimensOncological outcomesPrognostic significanceMedian ageSubunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes
Jann J, Hergott C, Winkler M, Liu Y, Braun B, Charles A, Copson K, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer E, Wadleigh M, Stone R, DeAngelo D, Garcia J, Haferlach T, Lindsley R, Luskin M, Stahl M, Tothova Z. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia 2024, 38: 1992-2002. PMID: 39033241, PMCID: PMC11347381, DOI: 10.1038/s41375-024-02347-y.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDana-Farber Cancer InstituteMyelodysplastic neoplasmsCohesin complex componentSubunit specificityAssociated with secondary AMLCohesin complexDe novo acute myeloid leukemiaSecondary acute myeloid leukemiaComplex mutationsCohesinGenetic driversGenetic characteristicsSTAG2 mutationsCo-occurrenceSubunit mutationsMutationsMyeloid malignanciesPrognostic significanceAdverse prognosisPrognostic classificationMyeloid leukemiaClinical characteristicsDana-FarberOntogenyNeuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer
Zhou Y, Zhang X, Gao Y, Peng Y, Liu P, Chen Y, Guo C, Deng G, Ouyang Y, Zhang Y, Han Y, Cai C, Shen H, Gao L, Zeng S. Neuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer. IScience 2024, 27: 110318. PMID: 39055918, PMCID: PMC11269305, DOI: 10.1016/j.isci.2024.110318.Peer-Reviewed Original ResearchNeuromedin U receptor 1Colorectal cancerCytotoxic T-lymphocyte-associated protein 4CD8<sup>+</sup> T cell infiltrationCD8<sup>+</sup> T cellsLymphocyte activation gene-3Improve immunotherapy outcomesT cell infiltrationComprehensive multi-omics analysisPersonalized immunotherapy strategiesPatient-derived tissuesColorectal cancer cell linesColorectal cancer treatmentImmunotherapy outcomesImmune checkpointsImmunotherapy efficacyImmunotherapy strategiesImmunotherapy responsePrognostic significanceImmune infiltrationT cellsMulti-omics analysisCell infiltrationGenetic alterationsHigh malignancyPlasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure
Lu Y, Xin J, Liang X, Luo J, Li P, Zhou X, Yang H, Li J, Wang Y. Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure. The Journal Of Infectious Diseases 2024, 230: 957-969. PMID: 38373244, DOI: 10.1093/infdis/jiae079.Peer-Reviewed Original ResearchHBV-ACLF patientsChronic hepatitis BAcute-on-chronic liver failureMer tyrosine kinaseHBV-ACLFArea under the receiver operating characteristic curveNormal controlsLiver failureLiver cirrhosisHBV-related acute-on-chronic liver failurePrognosis of HBV-ACLFHepatitis B-related acute-on-chronic liver failureRisk stratification analysesReceiver operating characteristic curveCut-off valueShort-term mortalityPrognostic rolePrognostic significancePrognostic valueHepatitis BPoor prognosisMerTK expressionImmunohistochemistry stainingDiagnostic accuracyDisease progression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply